School of Medicine Homepage
Emory University Shield
  • About
    • Our Vision
    • Academic Departments
    • Our Leadership
    • Health Care Partnerships
    • Diversity, Equity, & Inclusion
    • Location
    • Supporting Our People
    • Our Faculty
    • History
    • News
    • Events
    • Contact Us
  • Education
    • Degree and Certificate Programs
    • Academic Departments
    • Residents & Fellows
    • Postdoctoral Training
    • Continuing Medical Education
    • Admissions
    • Cost and Financial Aid
    • Student Resources
  • Research
    • Research Innovation
    • Conducting Research
    • Core Facilities
    • Research Centers
    • Research Training
    • Academic Departments
    • Find a Researcher
    • Research News
  • Clinical Experience
    • Where We Work
    • Caring for a Diverse Population
    • Faculty Clinical Experience
    • Advanced Patient Care
    • Academic Departments
    • Community Learning
  • Giving
  • Directory

Directory section navigation

  • Faculty Profiles

Emory University School of Medicine

  • About
    • Sub link
      Our Vision
    • Sub link
      Academic Departments
    • Sub link
      Our Leadership
    • Sub link
      Health Care Partnerships
    • Sub link
      Diversity, Equity, & Inclusion
    • Sub link
      Location
    • Sub link
      Supporting Our People
    • Sub link
      Our Faculty
    • Sub link
      History
    • Sub link
      News
    • Sub link
      Events
    • Sub link
      Contact Us
  • Education
    • Sub link
      Degree and Certificate Programs
    • Sub link
      Academic Departments
    • Sub link
      Residents & Fellows
    • Sub link
      Postdoctoral Training
    • Sub link
      Continuing Medical Education
    • Sub link
      Admissions
    • Sub link
      Cost and Financial Aid
    • Sub link
      Student Resources
  • Research
    • Sub link
      Research Innovation
    • Sub link
      Conducting Research
    • Sub link
      Core Facilities
    • Sub link
      Research Centers
    • Sub link
      Research Training
    • Sub link
      Academic Departments
    • Sub link
      Find a Researcher
    • Sub link
      Research News
  • Clinical Experience
    • Sub link
      Where We Work
    • Sub link
      Caring for a Diverse Population
    • Sub link
      Faculty Clinical Experience
    • Sub link
      Advanced Patient Care
    • Sub link
      Academic Departments
    • Sub link
      Community Learning
  • Giving
  • Directory
  • Home School of Medicine Home
  • Directory

Profile

Shi-Yong Sun PhD

  • Department of Hematology and Medical Oncology
    Professor
  • (404) 778-2170
  • ssun@emory.edu
Head shot of Shi-Yong Sun

Academic Appointment

  • Adjunct Professor, Department of Chemistry, College of Arts and Science, Georgia State University
  • Professor of Hematology and Oncology (Tenured), Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute

Education

Degrees

  • PhD from Peking Union Medical College (PUMC)/Chinese Academy of Medical Sciences (CAMS)
  • B.Sc from Lanzhou Medical College
  • MSc from Lanzhou Medical College

Research

Focus

  • Regulation of death receptor-mediated apoptotic pathway by small therapeutic molecules and their implications in drug-induced apoptosis and cancer therapy. b.Understanding relationship between mTOR and Akt and its impact on mTOR-targeted cancer therapy. c.Targeting eIF4E/translation initiation for cancer therapy.

Publications

  • Polo-like Kinase 1 Inhibitors Demonstrate In Vitro and In Vivo Efficacy in Preclinical Models of Small Cell Lung Cancer.
    Cancers (Basel) Volume: 17
    01/28/2025 Authors: Zhang G; Pannucci A; Ivanov AA; Switchenko J; Sun S-Y; Sica GL; Liu Z; Huang Y; Schmitz JC; Owonikoko TK
  • Intra-tumoral YAP and TAZ heterogeneity drives collective NSCLC invasion that is targeted by SUMOylation inhibitor TAK-981.
    iScience Volume: 27 Page(s): 111133
    11/15/2024 Authors: Sharma R; Sharma S; Shriwas P; Mehta L; Vu AH; Mouw JK; Koo J; Huang C; Matsuk VY; Tucker-Burden C
  • Inhibition of hTERT/telomerase/telomere mediates therapeutic efficacy of osimertinib in EGFR mutant lung cancer.
    J Exp Med Volume: 221
    11/04/2024 Authors: Chen Z; Vallega KA; Wang D; Quan Z; Fan S; Wang Q; Leal T; Ramalingam SS; Sun S-Y
  • Is tumor microenvironment important for targeted therapy in lung cancer?
    Cancer Lett Volume: 604 Page(s): 217203
    11/01/2024 Authors: Sun S-Y
  • Spatially resolved subcellular protein-protein interactomics in drug-perturbed lung-cancer cultures and tissues.
    Nat Biomed Eng
    10/30/2024 Authors: Cai S; Hu T; Venkataraman A; Rivera Moctezuma FG; Ozturk E; Zhang N; Wang M; Zvidzai T; Das S; Pillai A
  • Graph-Based Spatial Proximity of Super-Resolved Protein-Protein Interactions Predicts Cancer Drug Responses in Single Cells.
    Cell Mol Bioeng Volume: 17 Page(s): 467 - 490
    10/01/2024 Authors: Zhang N; Cai S; Wang M; Hu T; Schneider F; Sun S-Y; Coskun AF
  • Corrigendum to "Protein phosphatase 2A negatively regulates eukaryotic initiation factor 4E phosphorylation and eIF4F assembly through direct dephosphorylation of Mnk and eIF4E" [Neoplasia, volume 12, issue 10 (2010):848 -855].
    Neoplasia Volume: 56 Page(s): 101031
    10/01/2024 Authors: Li Y; Yue P; Deng X; Ueda T; Fukunaga R; Khuri FR; Sun S-Y
  • SHP2 ablation mitigates osteoarthritic cartilage degeneration by promoting chondrocyte anabolism through SOX9.
    FASEB J Volume: 38 Page(s): e70013
    09/15/2024 Authors: Wang L; Yang H; Wang C; Wang M; Huang J; Nyunt T; Osorio C; Sun S-Y; Pacifici M; Lefebvre V
  • Targeting Transient Receptor Potential Melastatin-2 (TRPM2) Enhances Therapeutic Efficacy of Third Generation EGFR Inhibitors against EGFR Mutant Lung Cancer.
    Adv Sci (Weinh) Volume: 11 Page(s): e2310126
    09/01/2024 Authors: Chen Z; Vallega KA; Boda VK; Quan Z; Wang D; Fan S; Wang Q; Ramalingam SS; Li W; Sun S-Y
  • DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer models.
    J Clin Invest Volume: 134
    03/07/2024 Authors: Chen Z; Vallega KA; Wang D; Quan Z; Fan S; Wang Q; Leal T; Ramalingam SS; Sun S-Y
  • ALK inhibitors downregulate the expression of death receptor 4 in ALK-mutant lung cancer cells via facilitating Fra-1 and c-Jun degradation and subsequent AP-1 suppression.
    Neoplasia Volume: 42 Page(s): 100908
    08/01/2023 Authors: Zhao W; Yu D; Zhai Y; Sun S-Y
  • Therapeutic potential of the novel Bcl-2/Bcl-XL dual inhibitor, APG1252, alone or in combination against non-small cell lung cancer.
    Mol Carcinog Volume: 61 Page(s): 1031 - 1042
    11/01/2022 Authors: Qian L; Vallega KA; Yao W; Wang D; Zhai Y; He X; Sun S-Y
  • Correction to: Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1.
    Cancer Gene Ther Volume: 29 Page(s): 1801 - 1802
    11/01/2022 Authors: Deng Y; Ma G; Vallega KA; Wang D; Wang M; Wang C; Wang S; Ramalingam SS; Sun S-Y
  • Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1.
    Cancer Gene Ther Volume: 29 Page(s): 1558 - 1569
    11/01/2022 Authors: Deng Y; Ma G; Vallega KA; Wang D; Wang M; Wang C; Wang S; Ramalingam SS; Sun S-Y
  • Targeting apoptosis to manage acquired resistance to third generation EGFR inhibitors.
    Front Med Volume: 16 Page(s): 701 - 713
    10/01/2022 Authors: Sun S-Y
  • Response to osimertinib plus trametinib in a heavily treated epidermal growth factor receptor (EGFR)-positive NSCLC harboring a rare, acquired rapidly accelerated fibrosarcoma B-type (BRAF) p.D594N mutation: a case report.
    Anticancer Drugs Volume: 33 Page(s): 963 - 965
    10/01/2022 Authors: Li S; Lin X; Sun S; Li S; Zhou C
  • Multiplexed protein profiling reveals spatial subcellular signaling networks.
    iScience Volume: 25 Page(s): 104980
    09/16/2022 Authors: Cai S; Hu T; Venkatesan M; Allam M; Schneider F; Ramalingam SS; Sun S-Y; Coskun AF
  • Mcl-1 levels critically impact the sensitivities of human colorectal cancer cells to APG-1252-M1, a novel Bcl-2/Bcl-XL dual inhibitor that induces Bax-dependent apoptosis.
    Neoplasia Volume: 29 Page(s): 100798
    07/01/2022 Authors: Yao W; Bai L; Wang S; Zhai Y; Sun S-Y
  • Overcoming acquired resistance to third-generation EGFR inhibitors by targeting activation of intrinsic apoptotic pathway through Mcl-1 inhibition, Bax activation, or both.
    Oncogene Volume: 41 Page(s): 1691 - 1700
    03/01/2022 Authors: Ma G; Deng Y; Qian L; Vallega KA; Zhang G; Deng X; Owonikoko TK; Ramalingam SS; Fang DD; Zhai Y
  • The natural product berberine synergizes with osimertinib preferentially against MET-amplified osimertinib-resistant lung cancer via direct MET inhibition.
    Pharmacol Res Volume: 175 Page(s): 105998
    01/01/2022 Authors: Chen Z; Vallega KA; Chen H; Zhou J; Ramalingam SS; Sun S-Y
  • Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib.
    Oncogene Volume: 40 Page(s): 6653 - 6665
    12/01/2021 Authors: Chen Z; Yu D; Owonikoko TK; Ramalingam SS; Sun S-Y
  • Inhibition of MEK5/ERK5 signaling overcomes acquired resistance to the third generation EGFR inhibitor, osimertinib, via enhancing Bim-dependent apoptosis.
    Cancer Lett Volume: 519 Page(s): 141 - 149
    10/28/2021 Authors: Zhao W; Yu D; Chen Z; Yao W; Yang J; Ramalingam SS; Sun S-Y
  • Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors.
    Mol Cancer Res Volume: 19 Page(s): 1622 - 1634
    10/01/2021 Authors: Qian G; Guo J; Vallega KA; Hu C; Chen Z; Deng Y; Wang Q; Fan S; Ramalingam SS; Owonikoko TK
  • Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib.
    Cancer Res Volume: 81 Page(s): 4822 - 4834
    09/15/2021 Authors: Zhu L; Chen Z; Zang H; Fan S; Gu J; Zhang G; Sun KD-Y; Wang Q; He Y; Owonikoko TK
  • Pan-cancer analysis of pathway-based gene expression pattern at the individual level reveals biomarkers of clinical prognosis.
    Cell Rep Methods Volume: 1
    08/23/2021 Authors: Su K; Yu Q; Shen R; Sun S-Y; Moreno CS; Li X; Qin ZS
  • MET inhibition downregulatesDR4 expression in MET-amplified lung cancer cells with acquired resistance to EGFR inhibitors through suppressing AP-1-mediated transcription.
    Neoplasia Volume: 23 Page(s): 766 - 774
    08/01/2021 Authors: Deng L; Vallega KA; Zhang S; Shi P; Sun S-Y
  • Nanoparticles for co-delivery of osimertinib and selumetinib to overcome osimertinib-acquired resistance in non-small cell lung cancer.
    Acta Biomater Volume: 129 Page(s): 258 - 268
    07/15/2021 Authors: Chen W; Yu D; Sun S-Y; Li F
  • Rictor, an essential component of mTOR complex 2, undergoes caspase-mediated cleavage during apoptosis induced by multiple stimuli.
    Apoptosis Volume: 26 Page(s): 338 - 347
    06/01/2021 Authors: Zhao L; Zhu L; Oh Y-T; Qian G; Chen Z; Sun S-Y
  • Corrigendum to "Inhibition of IGF1R enhances 2-deoxyglucose in the treatment of non-small cell lung cancer" [Lung Cancer 123 (2018) 36-43].
    Lung Cancer Volume: 154 Page(s): 227
    04/01/2021 Authors: Liu F; Liu Y; Liu X; Mao K; Zhong D; Marcus AI; Khuri FR; Sun S-Y; He Y; Zhou W
  • mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?
    Front Med Volume: 15 Page(s): 221 - 231
    04/01/2021 Authors: Sun S-Y
  • Regulation of Cancer Metastasis by TRAIL/Death Receptor Signaling.
    Biomolecules Volume: 11
    03/26/2021 Authors: Oh Y-T; Sun S-Y
  • YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell-Inflamed Phenotype.
    J Thorac Oncol Volume: 16 Page(s): 464 - 476
    03/01/2021 Authors: Owonikoko TK; Dwivedi B; Chen Z; Zhang C; Barwick B; Ernani V; Zhang G; Gilbert-Ross M; Carlisle J; Khuri FR
  • Erratum: GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth.
    Oncotarget Volume: 12 Page(s): 251 - 252
    02/02/2021 Authors: Koo J; Wang X; Owonikoko TK; Ramalingam SS; Khuri FR; Sun S-Y
  • Downregulation of death receptor 4 is tightly associated with positive response of EGFR mutant lung cancer to EGFR-targeted therapy and improved prognosis.
    Theranostics Volume: 11 Page(s): 3964 - 3980
    01/01/2021 Authors: Zhang S; Chen Z; Shi P; Fan S; He Y; Wang Q; Li Y; Ramalingam SS; Owonikoko TK; Sun S-Y
  • Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling.
    Lung Cancer (Auckl) Volume: 12 Page(s): 1 - 10
    01/01/2021 Authors: Yu D; Zhao W; Vallega KA; Sun S-Y
  • Inhibition of ACK1 delays and overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib.
    Lung Cancer Volume: 150 Page(s): 26 - 35
    12/01/2020 Authors: Gu J; Qian L; Zhang G; Mahajan NP; Owonikoko TK; Ramalingam SS; Sun S-Y
  • MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor-mutant lung cancers.
    Cancer Volume: 126 Page(s): 3788 - 3799
    08/15/2020 Authors: Gu J; Yao W; Shi P; Zhang G; Owonikoko TK; Ramalingam SS; Sun S-Y
  • Correction: Expression of death receptor 4 is positively regulated by MEK/ERK/AP-1 signaling and suppressed upon MEK inhibition.
    J Biol Chem Volume: 295 Page(s): 8871
    06/26/2020 Authors: Yao W; Oh Y-T; Deng J; Yue P; Deng L; Huang H; Zhou W; Sun S-Y
  • Correction: Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IB degradation.
    J Biol Chem Volume: 295 Page(s): 8869
    06/26/2020 Authors: Li C; Chen S; Yue P; Deng X; Lonial S; Khuri FR; Sun S-Y
  • Correction: Oncogenic Ras and B-Raf proteins positively regulate death receptor 5 expression through co-activation of ERK and JNK signaling.
    J Biol Chem Volume: 295 Page(s): 8870
    06/26/2020 Authors: Oh Y-T; Yue P; Zhou W; Balko JM; Black EP; Owonikoko TK; Khuri FR; Sun S-Y
  • BRD4 Levels Determine the Response of Human Lung Cancer Cells to BET Degraders That Potently Induce Apoptosis through Suppression of Mcl-1.
    Cancer Res Volume: 80 Page(s): 2380 - 2393
    06/01/2020 Authors: Zong D; Gu J; Cavalcante GC; Yao W; Zhang G; Wang S; Owonikoko TK; He X; Sun S-Y
  • Overcoming acquired resistance of EGFR-mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol.
    Mol Oncol Volume: 14 Page(s): 882 - 895
    04/01/2020 Authors: Zang H; Qian G; Arbiser J; Owonikoko TK; Ramalingam SS; Fan S; Sun S-Y
  • ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
    Cancer Volume: 126 Page(s): 1339 - 1350
    03/15/2020 Authors: Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun S-Y
  • A cell-permeable peptide-based PROTAC against the oncoprotein CREPT proficiently inhibits pancreatic cancer.
    Theranostics Volume: 10 Page(s): 3708 - 3721
    01/01/2020 Authors: Ma D; Zou Y; Chu Y; Liu Z; Liu G; Chu J; Li M; Wang J; Sun S-Y; Chang Z
  • Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589).
    Cancer Volume: 126 Page(s): 2024 - 2033
    01/01/2020 Authors: Zang H; Qian G; Zong D; Fan S; Owonikoko TK; Ramalingam SS; Sun S-Y
  • Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced -TrCP degradation.
    Oncogene Volume: 38 Page(s): 6270 - 6282
    08/01/2019 Authors: Deng L; Qian G; Zhang S; Zheng H; Fan S; Lesinski GB; Owonikoko TK; Ramalingam SS; Sun S-Y
  • mTORC2 Suppresses GSK3-Dependent Snail Degradation to Positively Regulate Cancer Cell Invasion and Metastasis.
    Cancer Res Volume: 79 Page(s): 3725 - 3736
    07/15/2019 Authors: Zhang S; Qian G; Zhang Q-Q; Yao Y; Wang D; Chen ZG; Wang L-J; Chen M; Sun S-Y
  • MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer.
    J Hematol Oncol Volume: 12 Page(s): 63
    06/21/2019 Authors: Wang Q; Yang S; Wang K; Sun S-Y
  • The Third-Generation EGFR Inhibitor, Osimertinib, Promotes c-FLIP Degradation, Enhancing Apoptosis Including TRAIL-Induced Apoptosis in NSCLC Cells with Activating EGFR Mutations.
    Transl Oncol Volume: 12 Page(s): 705 - 713
    05/01/2019 Authors: Shi P; Zhang S; Zhu L; Qian G; Ren H; Ramalingam SS; Chen M; Sun S-Y
  • PEST-containing nuclear protein regulates cell proliferation, migration, and invasion in lung adenocarcinoma.
    Oncogenesis Volume: 8 Page(s): 22
    03/14/2019 Authors: Wang D-Y; Hong Y; Chen Y-G; Dong P-Z; Liu S-Y; Gao Y-R; Lu D; Li H-M; Li T; Guo J-C
  • Tumour necrosis factor--induced protein 8-like 2 is a novel regulator of proliferation, migration, and invasion in human rectal adenocarcinoma cells.
    J Cell Mol Med Volume: 23 Page(s): 1698 - 1713
    03/01/2019 Authors: Wu D-D; Liu S-Y; Gao Y-R; Lu D; Hong Y; Chen Y-G; Dong P-Z; Wang D-Y; Li T; Li H-M
  • Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models.
    PLoS One Volume: 14 Page(s): e0206309
    01/01/2019 Authors: Owonikoko TK; Zhang G; Lallani SB; Chen Z; Martinson DE; Khuri FR; Lonial S; Marcus A; Sun S-Y
  • Co-inhibition of BET and proteasome enhances ER stress and Bim-dependent apoptosis with augmented cancer therapeutic efficacy.
    Cancer Lett Volume: 435 Page(s): 44 - 54
    10/28/2018 Authors: Qian G; Yao W; Zhang S; Bajpai R; Hall WD; Shanmugam M; Lonial S; Sun S-Y
  • Inhibition of IGF1R enhances 2-deoxyglucose in the treatment of non-small cell lung cancer.
    Lung Cancer Volume: 123 Page(s): 36 - 43
    09/01/2018 Authors: Liu F; Liu Y; Liu X; Mao K; Zhong D; Marcus AI; Khuri FR; Sun S-Y; He Y; Zhou W
  • Monocyte chemotactic protein-induced protein-1 enhances DR5 degradation and negatively regulates DR5 activation-induced apoptosis through its deubiquitinase function.
    Oncogene Volume: 37 Page(s): 3415 - 3425
    06/01/2018 Authors: Oh Y-T; Qian G; Deng J; Sun S-Y
  • 14-3-3 binds the proteasome, limits proteolytic function and enhances sensitivity to proteasome inhibitors.
    Leukemia Volume: 32 Page(s): 744 - 751
    03/01/2018 Authors: Gu Y; Xu K; Torre C; Samur M; Barwick BG; Rupji M; Arora J; Neri P; Kaufman J; Nooka A
  • Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation.
    Clin Cancer Res Volume: 23 Page(s): 6567 - 6579
    11/01/2017 Authors: Shi P; Oh Y-T; Deng L; Zhang G; Qian G; Zhang S; Ren H; Wu G; Legendre B; Anderson E
  • The proteasome deubiquitinase inhibitor b-AP15 enhances DR5 activation-induced apoptosis through stabilizing DR5.
    Sci Rep Volume: 7 Page(s): 8027
    08/14/2017 Authors: Oh Y-T; Deng L; Deng J; Sun S-Y
  • Inhibition of p70S6K does not mimic the enhancement of Akt phosphorylation by rapamycin.
    Heliyon Volume: 3 Page(s): e00378
    08/01/2017 Authors: Wang X; Yue P; Tao H; Sun S-Y
  • Modulation of Bax and mTOR for Cancer Therapeutics.
    Cancer Res Volume: 77 Page(s): 3001 - 3012
    06/01/2017 Authors: Li R; Ding C; Zhang J; Xie M; Park D; Ding Y; Chen G; Zhang G; Gilbert-Ross M; Zhou W
  • DR5 suppression induces sphingosine-1-phosphate-dependent TRAF2 polyubiquitination, leading to activation of JNK/AP-1 and promotion of cancer cell invasion.
    Cell Commun Signal Volume: 15 Page(s): 18
    05/08/2017 Authors: Oh Y-T; Yue P; Sun S-Y
  • Expression of Death Receptor 4 Is Positively Regulated by MEK/ERK/AP-1 Signaling and Suppressed upon MEK Inhibition.
    J Biol Chem Volume: 291 Page(s): 21694 - 21702
    10/07/2016 Authors: Yao W; Oh Y-T; Deng J; Yue P; Deng L; Huang H; Zhou W; Sun S-Y
  • Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
    Cancer Lett Volume: 380 Page(s): 494 - 504
    10/01/2016 Authors: Shi P; Oh Y-T; Zhang G; Yao W; Yue P; Li Y; Kanteti R; Riehm J; Salgia R; Owonikoko TK
  • Human papillomavirus oncoprotein E6 upregulates c-Met through p53 downregulation.
    Eur J Cancer Volume: 65 Page(s): 21 - 32
    09/01/2016 Authors: Qian G; Wang D; Magliocca KR; Hu Z; Nannapaneni S; Kim S; Chen Z; Sun S-Y; Shin DM; Saba NF
  • GPRC5A suppresses protein synthesis at the endoplasmic reticulum to prevent radiation-induced lung tumorigenesis.
    Nat Commun Volume: 7 Page(s): 11795
    06/08/2016 Authors: Wang J; Farris AB; Xu K; Wang P; Zhang X; Duong DM; Yi H; Shu H-K; Sun S-Y; Wang Y
  • Paradoxical activation of MEK/ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cells.
    Sci Rep Volume: 6 Page(s): 26803
    05/25/2016 Authors: Oh Y-T; Deng J; Yue P; Sun S-Y
  • Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer.
    J Transl Med Volume: 14 Page(s): 111
    05/03/2016 Authors: Owonikoko TK; Zhang G; Kim HS; Stinson RM; Bechara R; Zhang C; Chen Z; Saba NF; Pakkala S; Pillai R
  • Inhibition of mTOR complex 2 induces GSK3/FBXW7-dependent degradation of sterol regulatory element-binding protein 1 (SREBP1) and suppresses lipogenesis in cancer cells.
    Oncogene Volume: 35 Page(s): 642 - 650
    02/04/2016 Authors: Li S; Oh Y-T; Yue P; Khuri FR; Sun S-Y
  • Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing.
    Oncogene Volume: 35 Page(s): 459 - 467
    01/28/2016 Authors: Oh Y-T; Deng J; Yue P; Owonikoko TK; Khuri FR; Sun S-Y
  • Erratum.
    Autophagy Volume: 12 Page(s): 443
    01/01/2016
  • Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).
    Autophagy Volume: 12 Page(s): 1 - 222
    01/01/2016 Authors: Klionsky DJ; Abdelmohsen K; Abe A; Abedin MJ; Abeliovich H; Acevedo Arozena A; Adachi H; Adams CM; Adams PD; Adeli K
  • Suppression of death receptor 5 enhances cancer cell invasion and metastasis through activation of caspase-8/TRAF2-mediated signaling.
    Oncotarget Volume: 6 Page(s): 41324 - 41338
    12/01/2015 Authors: Oh Y-T; Yue P; Wang D; Tong J-S; Chen ZG; Khuri FR; Sun S-Y
  • The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition.
    Oncotarget Volume: 6 Page(s): 34669 - 34679
    10/27/2015 Authors: Yao W; Yue P; Khuri FR; Sun S-Y
  • Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K/Akt signaling in human lung cancer cells.
    Cancer Lett Volume: 364 Page(s): 70 - 78
    08/01/2015 Authors: Yao W; Yue P; Zhang G; Owonikoko TK; Khuri FR; Sun S-Y
  • Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds.
    Chem Biol Volume: 22 Page(s): 957 - 964
    07/23/2015 Authors: Lang L; Ding H-F; Chen X; Sun S-Y; Liu G; Yan C
  • The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5.
    Oncotarget Volume: 6 Page(s): 17532 - 17542
    07/10/2015 Authors: Han B; Yao W; Oh Y-T; Tong J-S; Li S; Deng J; Yue P; Khuri FR; Sun S-Y
  • mTOR Complex 2 Stabilizes Mcl-1 Protein by Suppressing Its Glycogen Synthase Kinase 3-Dependent and SCF-FBXW7-Mediated Degradation.
    Mol Cell Biol Volume: 35 Page(s): 2344 - 2355
    07/01/2015 Authors: Koo J; Yue P; Deng X; Khuri FR; Sun S-Y
  • Rictor Undergoes Glycogen Synthase Kinase 3 (GSK3)-dependent, FBXW7-mediated Ubiquitination and Proteasomal Degradation.
    J Biol Chem Volume: 290 Page(s): 14120 - 14129
    05/29/2015 Authors: Koo J; Wu X; Mao Z; Khuri FR; Sun S-Y
  • GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth.
    Oncotarget Volume: 6 Page(s): 8974 - 8987
    04/20/2015 Authors: Koo J; Wang X; Owonikoko TK; Ramalingam SS; Khuri FR; Sun S-Y
  • A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer.
    Clin Cancer Res Volume: 21 Page(s): 1859 - 1868
    04/15/2015 Authors: Owonikoko TK; Ramalingam SS; Miller DL; Force SD; Sica GL; Mendel J; Chen Z; Rogatko A; Tighiouart M; Harvey RD
  • Cables1 complex couples survival signaling to the cell death machinery.
    Cancer Res Volume: 75 Page(s): 147 - 158
    01/01/2015 Authors: Shi Z; Park HR; Du Y; Li Z; Cheng K; Sun S-Y; Li Z; Fu H; Khuri FR
  • Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck.
    Cancer Volume: 120 Page(s): 3940 - 3951
    12/15/2014 Authors: Saba NF; Hurwitz SJ; Magliocca K; Kim S; Owonikoko TK; Harvey D; Ramalingam SS; Chen Z; Rogerio J; Mendel J
  • Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer.
    Cancer Med Volume: 3 Page(s): 1579 - 1594
    12/01/2014 Authors: Owonikoko TK; Zhang G; Deng X; Rossi MR; Switchenko JM; Doho GH; Chen Z; Kim S; Strychor S; Christner SM
  • MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells.
    Blood Volume: 123 Page(s): 3269 - 3276
    05/22/2014 Authors: Gu Y; Kaufman JL; Bernal L; Torre C; Matulis SM; Harvey RD; Chen J; Sun S-Y; Boise LH; Lonial S
  • Maintaining glycogen synthase kinase-3 activity is critical for mTOR kinase inhibitors to inhibit cancer cell growth.
    Cancer Res Volume: 74 Page(s): 2555 - 2568
    05/01/2014 Authors: Koo J; Yue P; Gal AA; Khuri FR; Sun S-Y
  • c-FLIP links mTORC2 to apoptosis.
    Oncoscience Volume: 1 Page(s): 306 - 307
    01/01/2014 Authors: Zhao L; Sun S-Y
  • Prostate cancer metastatic to bone has higher expression of the calcium-sensing receptor (CaSR) than primary prostate cancer.
    Receptors Clin Investig Volume: 1
    01/01/2014 Authors: Feng J; Xu X; Li B; Brown E; Farris AB; Sun S-Y; Yang JJ
  • The E3 ubiquitin ligases -TrCP and FBXW7 cooperatively mediates GSK3-dependent Mcl-1 degradation induced by the Akt inhibitor API-1, resulting in apoptosis.
    Mol Cancer Volume: 12 Page(s): 146
    11/22/2013 Authors: Ren H; Koo J; Guan B; Yue P; Deng X; Chen M; Khuri FR; Sun S-Y
  • mTOR kinase inhibitors as potential cancer therapeutic drugs.
    Cancer Lett Volume: 340 Page(s): 1 - 8
    10/28/2013 Authors: Sun S-Y
  • Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer.
    Mol Cancer Ther Volume: 12 Page(s): 2200 - 2212
    10/01/2013 Authors: Li R; Hu Z; Sun S-Y; Chen ZG; Owonikoko TK; Sica GL; Ramalingam SS; Curran WJ; Khuri FR; Deng X
  • The PI3 kinase inhibitor NVP-BKM120 induces GSK3/FBXW7-dependent Mcl-1 degradation, contributing to induction of apoptosis and enhancement of TRAIL-induced apoptosis.
    Cancer Lett Volume: 338 Page(s): 229 - 238
    09/28/2013 Authors: Ren H; Zhao L; Li Y; Yue P; Deng X; Owonikoko TK; Chen M; Khuri FR; Sun S-Y
  • Novel small-molecule inhibitors of Bcl-XL to treat lung cancer.
    Cancer Res Volume: 73 Page(s): 5485 - 5496
    09/01/2013 Authors: Park D; Magis AT; Li R; Owonikoko TK; Sica GL; Sun S-Y; Ramalingam SS; Khuri FR; Curran WJ; Deng X
  • Blockade of glioma proliferation through allosteric inhibition of JAK2.
    Sci Signal Volume: 6 Page(s): ra55
    07/09/2013 Authors: He K; Qi Q; Chan C-B; Xiao G; Liu X; Tucker-Burden C; Wang L; Mao H; Lu X; McDonald FE
  • Protein phosphatase 2A and DNA-dependent protein kinase are involved in mediating rapamycin-induced Akt phosphorylation.
    J Biol Chem Volume: 288 Page(s): 13215 - 13224
    05/10/2013 Authors: Li Y; Wang X; Yue P; Tao H; Ramalingam SS; Owonikoko TK; Deng X; Wang Y; Fu H; Khuri FR
  • Impact of genetic alterations on mTOR-targeted cancer therapy.
    Chin J Cancer Volume: 32 Page(s): 270 - 274
    05/01/2013 Authors: Sun S-Y
  • Soluble FAS ligand as a biomarker of disease recurrence in differentiated thyroid cancer.
    Cancer Volume: 119 Page(s): 1503 - 1511
    04/15/2013 Authors: Owonikoko TK; Hossain MS; Bhimani C; Chen Z; Kim S; Ramalingam SS; Sun S-Y; Shin DM; Waller EK; Khuri FR
  • Prognostic impact of Fas-associated death domain, a key component in death receptor signaling, is dependent on the presence of lymph node metastasis in head and neck squamous cell carcinoma.
    Cancer Biol Ther Volume: 14 Page(s): 365 - 369
    04/01/2013 Authors: Fan S; Mller S; Chen ZG; Pan L; Tighiouart M; Shin DM; Khuri FR; Sun S-Y
  • mTOR complex 2 is involved in regulation of Cbl-dependent c-FLIP degradation and sensitivity of TRAIL-induced apoptosis.
    Cancer Res Volume: 73 Page(s): 1946 - 1957
    03/15/2013 Authors: Zhao L; Yue P; Khuri FR; Sun S-Y
  • Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer.
    J Thorac Oncol Volume: 8 Page(s): 369 - 372
    03/01/2013 Authors: Ramalingam SS; Owonikoko TK; Behera M; Subramanian J; Saba NF; Kono SA; Gal AA; Sica G; Harvey RD; Chen Z
  • The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo.
    Cancer Lett Volume: 325 Page(s): 139 - 146
    12/28/2012 Authors: Ren H; Chen M; Yue P; Tao H; Owonikoko TK; Ramalingam SS; Khuri FR; Sun S-Y
  • c-Myc suppression of DNA double-strand break repair.
    Neoplasia Volume: 14 Page(s): 1190 - 1202
    12/01/2012 Authors: Li Z; Owonikoko TK; Sun S-Y; Ramalingam SS; Doetsch PW; Xiao Z-Q; Khuri FR; Curran WJ; Deng X
  • Parp Enzyme Inhibitor, Veliparib (ABT-888), Potentiates the Efficacy Of Chemotherapy And Radiation In Small Cell Lung Cancer (SCLC)
    Volume: 7 Page(s): S278 - S278
    09/01/2012 Authors: Owonikoko TK; Zhang G; Deng X; Li C; Beumer JH; Rossi MR; Ramalingam SS; Curran WJ; Sun S; Khuri FR
  • K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas.
    Cancer Lett Volume: 322 Page(s): 58 - 69
    09/01/2012 Authors: Wei F; Liu Y; Bellail AC; Olson JJ; Sun S-Y; Lu G; Ding L; Yuan C; Wang G; Hao C
  • Downregulation of IRS-1 promotes metastasis of head and neck squamous cell carcinoma.
    Oncol Rep Volume: 28 Page(s): 659 - 667
    08/01/2012 Authors: Luo X; Fan S; Huang W; Zhai S; Ma Z; Li P; Sun S-Y; Wang X
  • NNK promotes migration and invasion of lung cancer cells through activation of c-Src/PKC/FAK loop.
    Cancer Lett Volume: 318 Page(s): 106 - 113
    05/01/2012 Authors: Shen J; Xu L; Owonikoko TK; Sun S-Y; Khuri FR; Curran WJ; Deng X
  • The novel Akt inhibitor API-1 induces c-FLIP degradation and synergizes with TRAIL to augment apoptosis independent of Akt inhibition
    CANCER RESEARCH Volume: 72
    04/15/2012 Authors: Li B; Rentsch H; Yue P; Chen M; Khuri FR; Sun S
  • The novel Akt inhibitor API-1 induces c-FLIP degradation and synergizes with TRAIL to augment apoptosis independent of Akt inhibition.
    Cancer Prev Res (Phila) Volume: 5 Page(s): 612 - 620
    04/01/2012 Authors: Li B; Ren H; Yue P; Chen M; Khuri FR; Sun S-Y
  • Guidelines for the use and interpretation of assays for monitoring autophagy.
    Autophagy Volume: 8 Page(s): 445 - 544
    04/01/2012 Authors: Klionsky DJ; Abdalla FC; Abeliovich H; Abraham RT; Acevedo-Arozena A; Adeli K; Agholme L; Agnello M; Agostinis P; Aguirre-Ghiso JA
  • Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer.
    Cancer Biol Ther Volume: 13 Page(s): 272 - 280
    03/01/2012 Authors: Li Y; Fan S; Koo J; Yue P; Chen ZG; Owonikoko TK; Ramalingam SS; Khuri FR; Sun S-Y
  • Acridine yellow G blocks glioblastoma growth via dual inhibition of epidermal growth factor receptor and protein kinase C kinases.
    J Biol Chem Volume: 287 Page(s): 6113 - 6127
    02/24/2012 Authors: Qi Q; He K; Yoo M-H; Chan C-B; Liu X; Zhang Z; Olson JJ; Xiao G; Wang L; Mao H
  • Oncogenic Ras and B-Raf proteins positively regulate death receptor 5 expression through co-activation of ERK and JNK signaling.
    J Biol Chem Volume: 287 Page(s): 257 - 267
    01/02/2012 Authors: Oh Y-T; Yue P; Zhou W; Balko JM; Black EP; Owonikoko TK; Khuri FR; Sun S-Y
  • Rapamycin induces Bad phosphorylation in association with its resistance to human lung cancer cells.
    Mol Cancer Ther Volume: 11 Page(s): 45 - 56
    01/01/2012 Authors: Liu Y; Sun S-Y; Owonikoko TK; Sica GL; Curran WJ; Khuri FR; Deng X
  • The NEDD8-activating enzyme inhibitor, MLN4924, cooperates with TRAIL to augment apoptosis through facilitating c-FLIP degradation in head and neck cancer cells.
    Mol Cancer Ther Volume: 10 Page(s): 2415 - 2425
    12/01/2011 Authors: Zhao L; Yue P; Lonial S; Khuri FR; Sun S-Y
  • Celecoxib promotes c-FLIP degradation through Akt-independent inhibition of GSK3.
    Cancer Res Volume: 71 Page(s): 6270 - 6281
    10/01/2011 Authors: Chen S; Cao W; Yue P; Hao C; Khuri FR; Sun S-Y
  • Pleiotropic functions of EAPII/TTRAP/TDP2: cancer development, chemoresistance and beyond.
    Cell Cycle Volume: 10 Page(s): 3274 - 3283
    10/01/2011 Authors: Li C; Sun S-Y; Khuri FR; Li R
  • Augmentation of NVP-BEZ235's anticancer activity against human lung cancer cells by blockage of autophagy.
    Cancer Biol Ther Volume: 12 Page(s): 549 - 555
    09/15/2011 Authors: Xu C-X; Zhao L; Yue P; Fang G; Tao H; Owonikoko TK; Ramalingam SS; Khuri FR; Sun S-Y
  • Oncogenic role of EAPII in lung cancer development and its activation of the MAPK-ERK pathway.
    Oncogene Volume: 30 Page(s): 3802 - 3812
    09/01/2011 Authors: Li C; Fan S; Owonikoko TK; Khuri FR; Sun S-Y; Li R
  • Retinoic acid enhances TRAIL-induced apoptosis in cancer cells by upregulating TRAIL receptor 1 expression.
    Cancer Res Volume: 71 Page(s): 5245 - 5254
    08/01/2011 Authors: Dhandapani L; Yue P; Ramalingam SS; Khuri FR; Sun S-Y
  • Combinatorial effects of lapatinib and rapamycin in triple-negative breast cancer cells.
    Mol Cancer Ther Volume: 10 Page(s): 1460 - 1469
    08/01/2011 Authors: Liu T; Yacoub R; Taliaferro-Smith LD; Sun S-Y; Graham TR; Dolan R; Lobo C; Tighiouart M; Yang L; Adams A
  • Everolimus, an mTOR inhibitor, in combination with docetaxel for second- or third-line therapy of advanced-stage non-small cell lung cancer: A phase II study.
    J Clin Oncol Volume: 29 Page(s): e13601
    05/20/2011 Authors: Khuri FR; Owonikoko TK; Subramanian J; Sica G; Behera M; Saba NF; Chen Z; Tighiouart M; Shin DM; Sun S
  • Drozitumab, a human antibody to death receptor 5, has potent antitumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of response.
    Clin Cancer Res Volume: 17 Page(s): 3181 - 3192
    05/15/2011 Authors: Kang Z; Chen J-J; Yu Y; Li B; Sun S-Y; Zhang B; Cao L
  • Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment.
    Mol Cancer Ther Volume: 10 Page(s): 902 - 914
    05/01/2011 Authors: Lu J; McEachern D; Sun H; Bai L; Peng Y; Qiu S; Miller R; Liao J; Yi H; Liu M
  • The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo.
    PLoS One Volume: 6 Page(s): e20899
    01/01/2011 Authors: Xu C-X; Li Y; Yue P; Owonikoko TK; Ramalingam SS; Khuri FR; Sun S-Y
  • ERK/ribosomal S6 kinase (RSK) signaling positively regulates death receptor 5 expression through co-activation of CHOP and Elk1.
    J Biol Chem Volume: 285 Page(s): 41310 - 41319
    12/31/2010 Authors: Oh Y-T; Liu X; Yue P; Kang S; Chen J; Taunton J; Khuri FR; Sun S-Y
  • c-Jun NH2-terminal kinase-dependent upregulation of DR5 mediates cooperative induction of apoptosis by perifosine and TRAIL.
    Mol Cancer Volume: 9 Page(s): 315
    12/20/2010 Authors: Fu L; Lin Y-D; Elrod HA; Yue P; Oh Y; Li B; Tao H; Chen GZ; Shin DM; Khuri FR
  • Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes.
    Blood Volume: 116 Page(s): 5285 - 5288
    12/09/2010 Authors: David E; Kaufman JL; Flowers CR; Schafer-Hales K; Torre C; Chen J; Marcus AI; Sun S-Y; Boise LH; Lonial S
  • Mono- or double-site phosphorylation distinctly regulates the proapoptotic function of Bax.
    PLoS One Volume: 5 Page(s): e13393
    10/14/2010 Authors: Wang Q; Sun S-Y; Khuri F; Curran WJ; Deng X
  • Protein phosphatase 2A negatively regulates eukaryotic initiation factor 4E phosphorylation and eIF4F assembly through direct dephosphorylation of Mnk and eIF4E.
    Neoplasia Volume: 12 Page(s): 848 - 855
    10/01/2010 Authors: Li Y; Yue P; Deng X; Ueda T; Fukunaga R; Khuri FR; Sun S-Y
  • GLI3-dependent repression of DR4 mediates hedgehog antagonism of TRAIL-induced apoptosis.
    Oncogene Volume: 29 Page(s): 4848 - 4858
    08/26/2010 Authors: Kurita S; Mott JL; Almada LL; Bronk SF; Werneburg NW; Sun S-Y; Roberts LR; Fernandez-Zapico ME; Gores GJ
  • Analysis of death receptor 5 and caspase-8 expression in primary and metastatic head and neck squamous cell carcinoma and their prognostic impact.
    PLoS One Volume: 5 Page(s): e12178
    08/16/2010 Authors: Elrod HA; Fan S; Muller S; Chen GZ; Pan L; Tighiouart M; Shin DM; Khuri FR; Sun S-Y
  • Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer.
    Cancer Volume: 116 Page(s): 3903 - 3909
    08/15/2010 Authors: Ramalingam SS; Harvey RD; Saba N; Owonikoko TK; Kauh J; Shin DM; Sun S-Y; Strychor S; Tighiouart M; Egorin MJ
  • DR5-mediated DISC controls caspase-8 cleavage and initiation of apoptosis in human glioblastomas.
    J Cell Mol Med Volume: 14 Page(s): 1303 - 1317
    06/01/2010 Authors: Bellail AC; Tse MCL; Song JH; Phuphanich S; Olson JJ; Sun SY; Hao C
  • Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation.
    J Biol Chem Volume: 285 Page(s): 16096 - 16104
    05/21/2010 Authors: Li C; Chen S; Yue P; Deng X; Lonial S; Khuri FR; Sun S-Y
  • c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589.
    PLoS One Volume: 5 Page(s): e10376
    04/28/2010 Authors: Kauh J; Fan S; Xia M; Yue P; Yang L; Khuri FR; Sun S-Y
  • The eIF4E/eIF4G interaction inhibitor 4EGI-1 augments TRAIL-mediated apoptosis through c-FLIP Down-regulation and DR5 induction independent of inhibition of cap-dependent protein translation.
    Neoplasia Volume: 12 Page(s): 346 - 356
    04/01/2010 Authors: Fan S; Li Y; Yue P; Khuri FR; Sun S-Y
  • p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells.
    J Clin Invest Volume: 120 Page(s): 1165 - 1177
    04/01/2010 Authors: Kang S; Elf S; Lythgoe K; Hitosugi T; Taunton J; Zhou W; Xiong L; Wang D; Muller S; Fan S
  • Dissecting the roles of DR4, DR5 and c-FLIP in the regulation of geranylgeranyltransferase I inhibition-mediated augmentation of TRAIL-induced apoptosis.
    Mol Cancer Volume: 9 Page(s): 23
    01/29/2010 Authors: Chen S; Fu L; Raja SM; Yue P; Khuri FR; Sun S-Y
  • N-acetylcysteine, reactive oxygen species and beyond.
    Cancer Biol Ther Volume: 9 Page(s): 109 - 110
    01/01/2010 Authors: Sun S-Y
  • eIF4E Expression Predicts Apoptosis in Response to Epidermal Growth Factor Receptor Inhibition and Mammalian Target of Rapamycin Inhibition in Triple Negative Breast Cancers
    Volume: 69 Page(s): 791S - 791S
    12/15/2009 Authors: Liu T; Yacoub R; Sun S-Y; Graham T; Tighiouart M; Yang L; O'Regan RM
  • Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy.
    Cancer Res Volume: 69 Page(s): 8967 - 8976
    12/01/2009 Authors: Fu L; Kim Y-A; Wang X; Wu X; Yue P; Lonial S; Khuri FR; Sun S-Y
  • Commentary on Perrone et al.: 'vitamin C: not for breakfast anymore...if you have myeloma'.
    Leukemia Volume: 23 Page(s): 1939 - 1940
    11/01/2009 Authors: Harvey RD; Nettles J; Wang B; Sun S-Y; Lonial S
  • Enhancing mTOR-targeted cancer therapy.
    Expert Opin Ther Targets Volume: 13 Page(s): 1193 - 1203
    10/01/2009 Authors: Wang X; Sun S-Y
  • Celecoxib antagonizes perifosine's anticancer activity involving a cyclooxygenase-2-dependent mechanism.
    Mol Cancer Ther Volume: 8 Page(s): 2575 - 2585
    09/01/2009 Authors: Elrod HA; Yue P; Khuri FR; Sun S-Y
  • The glycolytic inhibitor 2-deoxyglucose activates multiple prosurvival pathways through IGF1R.
    J Biol Chem Volume: 284 Page(s): 23225 - 23233
    08/28/2009 Authors: Zhong D; Xiong L; Liu T; Liu X; Liu X; Chen J; Sun S-Y; Khuri FR; Zong Y; Zhou Q
  • Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues.
    Cancer Biol Ther Volume: 8 Page(s): 1463 - 1469
    08/01/2009 Authors: Fan S; Ramalingam SS; Kauh J; Xu Z; Khuri FR; Sun S-Y
  • The role of cetuximab in the management of non-small-cell lung cancer.
    Clin Lung Cancer Volume: 10 Page(s): 230 - 238
    07/01/2009 Authors: Owonikoko TK; Sun S-Y; Ramalingam SS
  • Everolimus, an mTOR inhibitor, in combination with docetaxel for recurrent/refractory NSCLC: A phase I study.
    J Clin Oncol Volume: 27 Page(s): 8060
    05/20/2009 Authors: Khuri FR; Harvey RD; Saba NF; Owonikoko TK; Kauh J; Shin DM; Sun SY; Browning KM; Tighiouart M; Ramalingam SS
  • Everolimus, an mTOR inhibitor, in combination with docetaxel for recurrent/refractory NSCLC: A phase I study
    Volume: 27
    05/20/2009 Authors: Khuri FR; Harvey RD; Saba NF; Owonikoko TK; Kauh J; Shin DM; Sun SY; Browning KM; Tighiouart M; Ramalingam SS
  • Human BRE1 is an E3 ubiquitin ligase for Ebp1 tumor suppressor.
    Mol Biol Cell Volume: 20 Page(s): 757 - 768
    02/01/2009 Authors: Liu Z; Oh S-M; Okada M; Liu X; Cheng D; Peng J; Brat DJ; Sun S-Y; Zhou W; Gu W
  • Distinct growth factor-induced dynamic mass redistribution (DMR) profiles for monitoring oncogenic signaling pathways in various cancer cells.
    J Recept Signal Transduct Res Volume: 29 Page(s): 182 - 194
    01/01/2009 Authors: Du Y; Li Z; Li L; Chen ZG; Sun S-Y; Chen P; Shin DM; Khuri FR; Fu H
  • Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy.
    Cancer Biol Ther Volume: 7 Page(s): 1952 - 1958
    12/01/2008 Authors: Wang X; Hawk N; Yue P; Kauh J; Ramalingam SS; Fu H; Khuri FR; Sun S-Y
  • Restoration of caveolin-1 expression suppresses growth and metastasis of head and neck squamous cell carcinoma.
    Br J Cancer Volume: 99 Page(s): 1684 - 1694
    11/18/2008 Authors: Zhang H; Su L; Mller S; Tighiouart M; Xu Z; Zhang X; Shin HJC; Hunt J; Sun S-Y; Shin DM
  • Involvement of c-FLIP and survivin down-regulation in flexible heteroarotinoid-induced apoptosis and enhancement of TRAIL-initiated apoptosis in lung cancer cells.
    Mol Cancer Ther Volume: 7 Page(s): 3556 - 3565
    11/01/2008 Authors: Lin Y; Liu X; Yue P; Benbrook DM; Berlin KD; Khuri FR; Sun S-Y
  • Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation.
    Cancer Res Volume: 68 Page(s): 7409 - 7418
    09/15/2008 Authors: Wang X; Yue P; Kim YA; Fu H; Khuri FR; Sun S-Y
  • LKB1 is necessary for Akt-mediated phosphorylation of proapoptotic proteins.
    Cancer Res Volume: 68 Page(s): 7270 - 7277
    09/15/2008 Authors: Zhong D; Liu X; Khuri FR; Sun S-Y; Vertino PM; Zhou W
  • Coupling of endoplasmic reticulum stress to CDDO-Me-induced up-regulation of death receptor 5 via a CHOP-dependent mechanism involving JNK activation.
    Cancer Res Volume: 68 Page(s): 7484 - 7492
    09/15/2008 Authors: Zou W; Yue P; Khuri FR; Sun S-Y
  • Inhibition of IkappaB kinase-nuclear factor-kappaB signaling pathway by 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a novel monoketone analog of curcumin.
    Mol Pharmacol Volume: 74 Page(s): 654 - 661
    09/01/2008 Authors: Kasinski AL; Du Y; Thomas SL; Zhao J; Sun S-Y; Khuri FR; Wang C-Y; Shoji M; Sun A; Snyder JP
  • Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptors.
    Clin Cancer Res Volume: 14 Page(s): 5090 - 5098
    08/15/2008 Authors: David E; Sinha R; Chen J; Sun S-Y; Kaufman JL; Lonial S
  • CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells.
    Cancer Res Volume: 68 Page(s): 5335 - 5344
    07/01/2008 Authors: Lin Y-D; Chen S; Yue P; Zou W; Benbrook DM; Liu S; Le TC; Berlin KD; Khuri FR; Sun S-Y
  • The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor-induced apoptosis.
    Mol Cancer Ther Volume: 7 Page(s): 2212 - 2223
    07/01/2008 Authors: Raja SM; Chen S; Yue P; Acker TM; Lefkove B; Arbiser JL; Khuri FR; Sun S-Y
  • Gene expression profiling of non-small cell lung cancer.
    Lung Cancer Volume: 60 Page(s): 313 - 324
    06/01/2008 Authors: Singhal S; Miller D; Ramalingam S; Sun S-Y
  • Therapeutic potential of synthetic triterpenoids in neuroblastoma.
    Cancer Biol Ther Volume: 7 Page(s): 718 - 720
    05/01/2008 Authors: Sun S-Y
  • 2-Deoxyglucose induces Akt phosphorylation via a mechanism independent of LKB1/AMP-activated protein kinase signaling activation or glycolysis inhibition.
    Mol Cancer Ther Volume: 7 Page(s): 809 - 817
    04/01/2008 Authors: Zhong D; Liu X; Schafer-Hales K; Marcus AI; Khuri FR; Sun S-Y; Zhou W
  • Modulation of death receptors by cancer therapeutic agents.
    Cancer Biol Ther Volume: 7 Page(s): 163 - 173
    02/01/2008 Authors: Elrod HA; Sun S-Y
  • Down-regulation of 14-3-3zeta suppresses anchorage-independent growth of lung cancer cells through anoikis activation.
    Proc Natl Acad Sci U S A Volume: 105 Page(s): 162 - 167
    01/08/2008 Authors: Li Z; Zhao J; Du Y; Park HR; Sun S-Y; Bernal-Mizrachi L; Aitken A; Khuri FR; Fu H
  • Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation.
    Mol Cell Biol Volume: 27 Page(s): 7405 - 7413
    11/01/2007 Authors: Wang X; Yue P; Chan C-B; Ye K; Ueda T; Watanabe-Fukunaga R; Fukunaga R; Fu H; Khuri FR; Sun S-Y
  • CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non small-cell lung cancer cells.
    Mol Pharmacol Volume: 72 Page(s): 1269 - 1279
    11/01/2007 Authors: Chen S; Liu X; Yue P; Schnthal AH; Khuri FR; Sun S-Y
  • Akt phosphorylation regulates the tumour-suppressor merlin through ubiquitination and degradation.
    Nat Cell Biol Volume: 9 Page(s): 1199 - 1207
    10/01/2007 Authors: Tang X; Jang S-W; Wang X; Liu Z; Bahr SM; Sun S-Y; Brat D; Gutmann DH; Ye K
  • c-FLIP downregulation contributes to apoptosis induction by the novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me) in human lung cancer cells.
    Cancer Biol Ther Volume: 6 Page(s): 1614 - 1620
    10/01/2007 Authors: Zou W; Chen S; Liu X; Yue P; Sporn MB; Khuri FR; Sun S-Y
  • A double tyrosine phosphorylation of P68 RNA helicase confers resistance to TRAIL-induced apoptosis.
    Oncogene Volume: 26 Page(s): 6082 - 6092
    09/06/2007 Authors: Yang L; Lin C; Sun S-Y; Zhao S; Liu Z-R
  • Chemotherapy-resistant side-population of colon cancer cells has a higher sensitivity to TRAIL than the non-SP, a higher expression of c-Myc and TRAIL-receptor DR4.
    Cancer Biol Ther Volume: 6 Page(s): 1490 - 1495
    09/01/2007 Authors: Sussman RT; Ricci MS; Hart LS; Sun SY; El-Deiry WS
  • The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway.
    Mol Cancer Ther Volume: 6 Page(s): 2029 - 2038
    07/01/2007 Authors: Elrod HA; Lin Y-D; Yue P; Wang X; Lonial S; Khuri FR; Sun S-Y
  • The farnesyltransferase inhibitor lonafarnib induces CCAAT/enhancer-binding protein homologous protein-dependent expression of death receptor 5, leading to induction of apoptosis in human cancer cells.
    J Biol Chem Volume: 282 Page(s): 18800 - 18809
    06/29/2007 Authors: Sun S-Y; Liu X; Zou W; Yue P; Marcus AI; Khuri FR
  • The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
    Cancer Res Volume: 67 Page(s): 4981 - 4988
    05/15/2007 Authors: Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun S-Y
  • The farnesyltransferase inhibitor R115777 up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer cells.
    Cancer Res Volume: 67 Page(s): 4973 - 4980
    05/15/2007 Authors: Qiu Y; Liu X; Zou W; Yue P; Lonial S; Khuri FR; Sun S-Y
  • Assessment of apoptosis-inducing effects of docetaxel combined with the proteasome inhibitor PS-341 in human lung cancer cells.
    Cancer Biol Ther Volume: 6 Page(s): 749 - 754
    05/01/2007 Authors: Jung CS; Zhou Z; Khuri FR; Sun S-Y
  • Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells.
    Cancer Volume: 109 Page(s): 1279 - 1289
    04/01/2007 Authors: Shigemura K; Arbiser JL; Sun S-Y; Zayzafoon M; Johnstone PAS; Fujisawa M; Gotoh A; Weksler B; Zhau HE; Chung LWK
  • PPARgamma ligands enhance TRAIL-induced apoptosis through DR5 upregulation and c-FLIP downregulation in human lung cancer cells.
    Cancer Biol Ther Volume: 6 Page(s): 99 - 106
    01/01/2007 Authors: Zou W; Liu X; Yue P; Khuri FR; Sun S-Y
  • Cellular FLICE-inhibitory protein down-regulation contributes to celecoxib-induced apoptosis in human lung cancer cells.
    Cancer Res Volume: 66 Page(s): 11115 - 11119
    12/01/2006 Authors: Liu X; Yue P; Schnthal AH; Khuri FR; Sun S-Y
  • LKB1 mutation in large cell carcinoma of the lung.
    Lung Cancer Volume: 53 Page(s): 285 - 294
    09/01/2006 Authors: Zhong D; Guo L; de Aguirre I; Liu X; Lamb N; Sun S-Y; Gal AA; Vertino PM; Zhou W
  • Targeting protein-protein interactions in signaling pathways for therapeutic interventions
    ACTA PHARMACOLOGICA SINICA Volume: 27 Page(s): 26 - 26
    07/01/2006 Authors: Du Y; Luhn P; Park H; Sun S; Khuri FR; Fu H
  • A novel DNMT3B subfamily, DeltaDNMT3B, is the predominant form of DNMT3B in non-small cell lung cancer.
    Int J Oncol Volume: 29 Page(s): 201 - 207
    07/01/2006 Authors: Wang L; Wang J; Sun S; Rodriguez M; Yue P; Jang SJ; Mao L
  • Depletion of intracellular glutathione contributes to JNK-mediated death receptor 5 upregulation and apoptosis induction by the novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me).
    Cancer Biol Ther Volume: 5 Page(s): 492 - 497
    05/01/2006 Authors: Yue P; Zhou Z; Khuri FR; Sun S-Y
  • Homozygous deletion of LKB1 mutation in H157 lung cancer cell line
    Volume: 66
    04/01/2006 Authors: Zhong D; Guo L; de Aguirre I; Liu X; Lamb N; Sun S; Gal A; Vertino PM; Zhou W
  • Targeting mTOR signaling for lung cancer therapy.
    J Thorac Oncol Volume: 1 Page(s): 109 - 111
    02/01/2006 Authors: Sun S-Y; Fu H; Khuri FR
  • Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells.
    Clin Cancer Res Volume: 12 Page(s): 273 - 280
    01/01/2006 Authors: Zou W; Yue P; Lin N; He M; Zhou Z; Lonial S; Khuri FR; Wang B; Sun S-Y
  • The role of death receptor 5-mediated extrinsic apoptotic pathway in farnesyltransferase inhibitor-induced apoptosis in human cancer cells.
    Volume: 11 Page(s): 9017S - 9017S
    12/15/2005 Authors: Sun SY; Liu XG; Yue P; Zhou ZM; Zou W; Marcus AI; Khur FR
  • The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT.
    Blood Volume: 106 Page(s): 4322 - 4329
    12/15/2005 Authors: David E; Sun S-Y; Waller EK; Chen J; Khuri FR; Lonial S
  • Chemopreventive agent-induced modulation of death receptors.
    Apoptosis Volume: 10 Page(s): 1203 - 1210
    12/01/2005 Authors: Sun S-Y
  • Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity.
    Cancer Res Volume: 65 Page(s): 9169 - 9175
    10/15/2005 Authors: Liu X; Yue P; Khuri FR; Sun S-Y
  • Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model.
    Clin Cancer Res Volume: 11 Page(s): 6261 - 6269
    09/01/2005 Authors: Zhang X; Chen ZG; Choe MS; Lin Y; Sun S-Y; Wieand HS; Shin HJC; Chen A; Khuri FR; Shin DM
  • Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
    Cancer Res Volume: 65 Page(s): 7052 - 7058
    08/15/2005 Authors: Sun S-Y; Rosenberg LM; Wang X; Zhou Z; Yue P; Fu H; Khuri FR
  • Activation of nuclear factor-kappaB contributes to induction of death receptors and apoptosis by the synthetic retinoid CD437 in DU145 human prostate cancer cells.
    Cancer Res Volume: 65 Page(s): 6354 - 6363
    07/15/2005 Authors: Jin F; Liu X; Zhou Z; Yue P; Lotan R; Khuri FR; Chung LWK; Sun S-Y
  • Enhanced growth inhibition and apoptosis induction in NSCLC cell lines by combination of celecoxib and 4HPR at clinically relevant concentrations.
    Cancer Biol Ther Volume: 4 Page(s): 407 - 413
    04/01/2005 Authors: Sun S-Y; Schroeder CP; Yue P; Lotan D; Hong WK; Lotan R
  • Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells.
    J Natl Cancer Inst Volume: 96 Page(s): 1769 - 1780
    12/01/2004 Authors: Liu X; Yue P; Zhou Z; Khuri FR; Sun S-Y
  • Hypermethylation of the death-associated protein kinase promoter attenuates the sensitivity to TRAIL-induced apoptosis in human non-small cell lung cancer cells.
    Mol Cancer Res Volume: 2 Page(s): 685 - 691
    12/01/2004 Authors: Tang X; Wu W; Sun S-Y; Wistuba II; Hong WK; Mao L
  • Combination of farnesyl transferase inhibition (lonafarnib) and proteasome inhibition (bortezomib) results in rapid caspase activation and down regulation of p-AKT in myeloma cell lines and primary myeloma cells.
    Volume: 104 Page(s): 678A - 678A
    11/16/2004 Authors: David E; Sun SY; Khuri FR; Lonial S
  • The farnesyltransferase inhibitor Lonafarnib induces growth arrest or apoptosis of human lung cancer cells without downregulation of Akt.
    Cancer Biol Ther Volume: 3 Page(s): 1092 - 1098
    11/01/2004 Authors: Sun S-Y; Zhou Z; Wang R; Fu H; Khuri FR
  • c-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells.
    Cancer Res Volume: 64 Page(s): 7570 - 7578
    10/15/2004 Authors: Zou W; Liu X; Yue P; Zhou Z; Sporn MB; Lotan R; Khuri FR; Sun S-Y
  • p53 upregulates death receptor 4 expression through an intronic p53 binding site.
    Cancer Res Volume: 64 Page(s): 5078 - 5083
    08/01/2004 Authors: Liu X; Yue P; Khuri FR; Sun S-Y
  • Apoptosis as a novel target for cancer chemoprevention.
    J Natl Cancer Inst Volume: 96 Page(s): 662 - 672
    05/05/2004 Authors: Sun S-Y; Hail N; Lotan R
  • Retinoic acid receptor beta and colon cancer.
    Cancer Biol Ther Volume: 3 Page(s): 87 - 88
    01/01/2004 Authors: Sun S-Y
  • Targeting 14-3-3/ligand interactions in NSCLC.
    Volume: 9 Page(s): 6242S - 6242S
    12/01/2003 Authors: Park HR; Luhn PA; Zhang HY; Montoya LM; Sun SY; Khuri FR; Fu H
  • The farnesyltransferase inhibitor lonafarnib induces growth inhibition and apoptosis in human lung cancer cells without downregulating
    Volume: 9 Page(s): 6095S - 6095S
    12/01/2003 Authors: Sun SY; Zhou ZM; Wang RX; Khuri FR
  • Evidence that the human death receptor 4 is regulated by activator protein 1.
    Oncogene Volume: 21 Page(s): 3121 - 3129
    05/09/2002 Authors: Guan B; Yue P; Lotan R; Sun S-Y
  • The synthetic retinoid CD437 selectively induces apoptosis in human lung cancer cells while sparing normal human lung epithelial cells.
    Cancer Res Volume: 62 Page(s): 2430 - 2436
    04/15/2002 Authors: Sun S-Y; Yue P; Chen X; Hong WK; Lotan R
  • Identification of a novel synthetic triterpenoid, methyl-2-cyano-3,12-dioxooleana-1,9-dien-28-oate, that potently induces caspase-mediated apoptosis in human lung cancer cells.
    Mol Cancer Ther Volume: 1 Page(s): 177 - 184
    01/01/2002 Authors: Kim KB; Lotan R; Yue P; Sporn MB; Suh N; Gribble GW; Honda T; Wu GS; Hong WK; Sun S-Y
  • Retinoids and their receptors in cancer development and chemoprevention.
    Crit Rev Oncol Hematol Volume: 41 Page(s): 41 - 55
    01/01/2002 Authors: Sun S-Y; Lotan R
  • How much do we know about retinoid-regulated genes?
    Cancer Biol Ther Volume: 1 Page(s): 28 - 30
    01/01/2002 Authors: Sun SY
  • Effects of N-(4-hydroxyphenyl)retinamide on hTERT expression in the bronchial epithelium of cigarette smokers.
    J Natl Cancer Inst Volume: 93 Page(s): 1257 - 1263
    08/15/2001 Authors: Soria JC; Moon C; Wang L; Hittelman WN; Jang SJ; Sun SY; Lee JJ; Liu D; Kurie JM; Morice RC
  • All-trans-retinoic acid enhances the effect of adenovirus-mediated wild-type p53 gene transfer in head and neck squamous cell carcinoma.
    Laryngoscope Volume: 111 Page(s): 1459 - 1464
    08/01/2001 Authors: Nakashima T; Sun SY; Lotan R; Fujiwara T; Yasumatsu R; Komiyama S; Clayman GL
  • Evidence that the death receptor DR4 is a DNA damage-inducible, p53-regulated gene.
    J Cell Physiol Volume: 188 Page(s): 98 - 105
    07/01/2001 Authors: Guan B; Yue P; Clayman GL; Sun SY
  • Identification of retinamides that are more potent than N-(4-hydroxyphenyl)retinamide in inhibiting growth and inducing apoptosis of human head and neck and lung cancer cells.
    Cancer Epidemiol Biomarkers Prev Volume: 10 Page(s): 595 - 601
    06/01/2001 Authors: Sun SY; Yue P; Kelloff GJ; Steele VE; Lippman SM; Hong WK; Lotan R
  • Overexpression of BCL2 blocks TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells.
    Biochem Biophys Res Commun Volume: 280 Page(s): 788 - 797
    01/26/2001 Authors: Sun SY; Yue P; Zhou JY; Wang Y; Choi Kim HR; Lotan R; Wu GS
  • Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells.
    Cancer Res Volume: 60 Page(s): 7149 - 7155
    12/15/2000 Authors: Sun SY; Yue P; Hong WK; Lotan R
  • Induction of Fas expression and augmentation of Fas/Fas ligand-mediated apoptosis by the synthetic retinoid CD437 in human lung cancer cells.
    Cancer Res Volume: 60 Page(s): 6537 - 6543
    11/15/2000 Authors: Sun SY; Yue P; Hong WK; Lotan R
  • Implication of multiple mechanisms in apoptosis induced by the synthetic retinoid CD437 in human prostate carcinoma cells.
    Oncogene Volume: 19 Page(s): 4513 - 4522
    09/14/2000 Authors: Sun SY; Yue P; Lotan R
  • Dual mechanisms of action of the retinoid CD437: nuclear retinoic acid receptor-mediated suppression of squamous differentiation and receptor-independent induction of apoptosis in UMSCC22B human head and neck squamous cell carcinoma cells.
    Mol Pharmacol Volume: 58 Page(s): 508 - 514
    09/01/2000 Authors: Sun SY; Yue P; Chandraratna RA; Tesfaigzi Y; Hong WK; Lotan R
  • Evidence that retinoic acid receptor beta induction by retinoids is important for tumor cell growth inhibition.
    J Biol Chem Volume: 275 Page(s): 17149 - 17153
    06/02/2000 Authors: Sun SY; Wan H; Yue P; Hong WK; Lotan R
  • Identification of receptor-selective retinoids that are potent inhibitors of the growth of human head and neck squamous cell carcinoma cells.
    Clin Cancer Res Volume: 6 Page(s): 1563 - 1573
    04/01/2000 Authors: Sun SY; Yue P; Mao L; Dawson MI; Shroot B; Lamph WW; Heyman RA; Chandraratna RA; Shudo K; Hong WK
  • Implication of c-Myc in apoptosis induced by the retinoid CD437 in human lung carcinoma cells.
    Oncogene Volume: 18 Page(s): 3894 - 3901
    07/01/1999 Authors: Sun SY; Yue P; Shroot B; Hong WK; Lotan R
  • Implication of p53 in growth arrest and apoptosis induced by the synthetic retinoid CD437 in human lung cancer cells.
    Cancer Res Volume: 59 Page(s): 2829 - 2833
    06/15/1999 Authors: Sun SY; Yue P; Wu GS; El-Deiry WS; Shroot B; Hong WK; Lotan R
  • Mediation of N-(4-hydoxyphenyl)retinamide-induced apoptosis in human cancer cells by different mechanisms.
    Cancer Res Volume: 59 Page(s): 2493 - 2498
    05/15/1999 Authors: Sun SY; Li W; Yue P; Lippman SM; Hong WK; Lotan R
  • Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells.
    Oncogene Volume: 18 Page(s): 2357 - 2365
    04/08/1999 Authors: Sun SY; Yue P; Wu GS; El-Deiry WS; Shroot B; Hong WK; Lotan R
  • Induction of apoptosis by N-(4-hydroxyphenyl)retinamide and its association with reactive oxygen species, nuclear retinoic acid receptors, and apoptosis-related genes in human prostate carcinoma cells.
    Mol Pharmacol Volume: 55 Page(s): 403 - 410
    03/01/1999 Authors: Sun SY; Yue P; Lotan R
  • Differential responses of normal, premalignant, and malignant human bronchial epithelial cells to receptor-selective retinoids.
    Clin Cancer Res Volume: 5 Page(s): 431 - 437
    02/01/1999 Authors: Sun SY; Kurie JM; Yue P; Dawson MI; Shroot B; Chandraratna RA; Hong WK; Lotan R
  • Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells.
    Cancer Res Volume: 57 Page(s): 4931 - 4939
    11/01/1997 Authors: Sun SY; Yue P; Dawson MI; Shroot B; Michel S; Lamph WW; Heyman RA; Teng M; Chandraratna RA; Shudo K
  • Induction of apoptosis in human non-small cell lung carcinoma cells by the novel synthetic retinoid CD437.
    Volume: 173 Page(s): 279 - 284
    11/01/1997 Authors: Sun SY; Yue P; Shroot B; Hong WK; Lotan R
  • [Anti-oxidative effects of R8605, a third-generation retinoid].
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao Volume: 15 Page(s): 58 - 62
    02/01/1993 Authors: Sun S; Han R
  • [Anti-carcinogenic and anti-promoting effects of retinoid R8605].
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao Volume: 14 Page(s): 365 - 370
    10/01/1992 Authors: Sun S; Han R
Read more publications Fewer publications
Directory
  • Faculty Profiles
Emory University Homepage

Contact & Location

Emory University School of Medicine
100 Woodruff Circle
Atlanta, GA  30322 USA
  • Contact Us
  • Maps & Directions
  • Careers

Information For

  • Alumni
  • Faculty & Staff
  • Patients
  • Residents & Fellows
  • Students
Support the School of Medicine School of Medicine Intranet
facebook facebook twitter twitter linkedin linkedin instagram instagram youtube youtube
© 2025 Emory University
  • Privacy Policy
  • Emergency Information
  • EEO Employer-Disability/Veteran Statements